This Application Note describes a method for the fast analysis of chemotherapy drugs using Agilent Polaris and Agilent Pursuit columns. The method allows for the differentiation of cancer drugs in less than three minutes and can be used to assess the quality of drug preparations. The development of this method is a major step in improving the quality of drug delivery for cancer patients.
This document presents an application note detailing a method for the fast analysis of intravenous chemotherapy drugs. Developed by researchers at the Hôpital Européen Georges Pompidou, the method aims to verify drug quality in less than three minutes to improve patient care and reduce delays. The study focuses on differentiating chemically similar drugs that are difficult to resolve using standard Flow Injection Analysis (FIA).
| Mobile Phase (Cyclophosphamide/Ifosfamide) | H2O:ACN 75:25 v/v |
|---|---|
| Flow Rate (Cyclophosphamide/Ifosfamide) | 1.0 mL/min |
| Pressure (Cyclophosphamide/Ifosfamide) | 45 bar |
| Injection Volume (Cyclophosphamide/Ifosfamide) | 10 µL |
| Mobile Phase (Doxorubicin/Epirubicin) | Sodium phosphate buffer 0.1 M, pH 7.5:ACN 75:25 v/v |
| Flow Rate (Doxorubicin/Epirubicin) | 0.8 mL/min |
| Pressure (Doxorubicin/Epirubicin) | 250 bar |
| Injection Volume (Doxorubicin/Epirubicin) | 50 µL |
| Analysis Time (Cyclophosphamide/Ifosfamide) | 1.8 minutes |
| Analysis Time (Doxorubicin/Epirubicin) | 2.5 minutes |
The analysis time for cyclophosphamide and ifosfamide is 1.8 minutes.
The analysis time for doxorubicin and epirubicin is 2.5 minutes.
The study chose cyclophosphamide and ifosfamide, and doxorubicin and epirubicin as test mixtures.